Literature DB >> 9755101

Phosphodiesterase expression in human epithelial cells.

L C Wright1, J Seybold, A Robichaud, I M Adcock, P J Barnes.   

Abstract

Epithelial cells play a critical role in airway inflammation and have the capacity to produce many inflammatory mediators, including bioactive lipids and proinflammatory cytokines. Intracellular levels of cAMP and cGMP are important in the control of inflammatory cell function. These cyclic nucleotides are inactivated via a family of phosphodiesterase (PDE) enzymes, providing a possible site for drug intervention in chronic inflammatory conditions. We studied the expression of PDE activity in an epithelial cell line (A549) and in primary human airway epithelial cells (HAECs). We measured PDE function using specific inhibitors to identify the PDE families present and used RT-PCR to elucidate the expression of PDE isogenes. Both A549 cells and HAECs predominantly expressed PDE4 activity, with lesser PDE1, PDE3, and PDE5 activity. RT-PCR identified HSPDE4A5 and HSPDE4D3 together with HSPDE7. Inhibition of PDE4 and PDE3 reduced secretion by these cells. Epithelial PDE may be an important target for PDE4 inhibitors in the development of the control of asthmatic inflammation, particularly when delivered via the inhaled route.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755101     DOI: 10.1152/ajplung.1998.275.4.L694

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  15 in total

1.  A pathophysiological role of PDE3 in allergic airway inflammation.

Authors:  Jan Beute; Melanie Lukkes; Ewout P Koekoek; Hedwika Nastiti; Keerthana Ganesh; Marjolein Jw de Bruijn; Steve Hockman; Menno van Nimwegen; Gert-Jan Braunstahl; Louis Boon; Bart N Lambrecht; Vince C Manganiello; Rudi W Hendriks; Alex KleinJan
Journal:  JCI Insight       Date:  2018-01-25

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 3.  Clinical pharmacology of Cilomilast.

Authors:  Geoff Down; Sarah Siederer; Sam Lim; Peter Daley-Yates
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

6.  Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model.

Authors:  Rui Lin; Hui Peng; Long P Nguyen; Noor B Dudekula; Felix Shardonofsky; Brian J Knoll; Sergio Parra; Richard A Bond
Journal:  Pulm Pharmacol Ther       Date:  2007-07-04       Impact factor: 3.410

7.  East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease.

Authors:  Manju Sharma; Corey Levenson; John C Browning; Emily M Becker; Ian Clements; Paul Castella; Michael E Cox
Journal:  Front Pharmacol       Date:  2018-03-09       Impact factor: 5.810

8.  PDE3 Inhibition Reduces Epithelial Mast Cell Numbers in Allergic Airway Inflammation and Attenuates Degranulation of Basophils and Mast Cells.

Authors:  Jan Beute; Keerthana Ganesh; Hedwika Nastiti; Robin Hoogenboom; Vivica Bos; Jelle Folkerts; Marco W J Schreurs; Steve Hockman; Rudi W Hendriks; Alex KleinJan
Journal:  Front Pharmacol       Date:  2020-05-01       Impact factor: 5.810

9.  Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains.

Authors:  Himabindu Penmatsa; Weiqiang Zhang; Sunitha Yarlagadda; Chunying Li; Veronica G Conoley; Junming Yue; Suleiman W Bahouth; Randal K Buddington; Guangping Zhang; Deborah J Nelson; Monal D Sonecha; Vincent Manganiello; Jeffrey J Wine; Anjaparavanda P Naren
Journal:  Mol Biol Cell       Date:  2010-01-20       Impact factor: 4.138

10.  Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.

Authors:  Manuel Mata; Isidoro Martinez; Jose A Melero; Herman Tenor; Julio Cortijo
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.